2017
Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction
Kernan WN, Viscoli CM, Dearborn JL, Kent DM, Conwit R, Fayad P, Furie KL, Gorman M, Guarino PD, Inzucchi SE, Stuart A, Young LH. Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. JAMA Neurology 2017, 74: 1319-1327. PMID: 28975241, PMCID: PMC5710663, DOI: 10.1001/jamaneurol.2017.2136.Peer-Reviewed Original ResearchConceptsTransient ischemic attackIschemic attackMyocardial infarctionIschemic strokeHigh riskPioglitazone groupInsulin resistanceLower riskCox proportional hazards regression modelProportional hazards regression modelsMedian riskEfficacy of pioglitazoneInsulin Resistance InterventionQualifying ischemic strokePlacebo-controlled trialHazards regression modelsLow baseline riskType 2 diabetesGreater absolute benefitDay of entryFuture strokeHydrochloride therapyPlacebo groupHazard ratioSecondary preventionCardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack
Young LH, Viscoli CM, Curtis JP, Inzucchi SE, Schwartz GG, Lovejoy AM, Furie KL, Gorman MJ, Conwit R, Abbott JD, Jacoby DL, Kolansky DM, Pfau SE, Ling FS, Kernan WN. Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack. Circulation 2017, 135: 1882-1893. PMID: 28246237, PMCID: PMC5511545, DOI: 10.1161/circulationaha.116.024863.Peer-Reviewed Original ResearchConceptsAcute coronary syndromeType 1 myocardial infarctionTransient ischemic attackMyocardial infarctionCoronary syndromeInsulin resistanceIschemic attackIschemic strokeDiabetes mellitusSerum troponinAcute coronary syndrome episodeMean age 63 yearsAcute coronary syndrome eventIndependent clinical events committeeType 2 myocardial infarctionIRIS participantsImpact of pioglitazoneRecent cerebrovascular eventsRecent ischemic strokeClinical events committeeAge 63 yearsEffect of pioglitazoneSmall myocardial infarctionCoronary artery diseaseST-segment elevation
1993
Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness.
Viscoli CM, Horwitz RI, Singer BH. Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness. Annals Of Internal Medicine 1993, 118: 99-105. PMID: 8416325, DOI: 10.7326/0003-4819-118-2-199301150-00004.Peer-Reviewed Original ResearchConceptsBeta-blocker therapyClinical courseVital statusMyocardial infarctionLong-term beneficial effectsPlacebo-controlled trialRecurrent ischemic eventsInitiation of therapyCongestive heart failureHeart Attack TrialLong-term therapeutic benefitHeterogeneous clinical courseYears of ageLong-term effectivenessEligible patientsSevere comorbiditiesBeta blockersIschemic eventsHeart failureTrial entryAttack TrialClinical centersSubsequent riskWomen 30High risk
1992
Problems in the conduct and analysis of randomized clinical trials. Are we getting the right answers to the wrong questions?
Rabeneck L, Viscoli CM, Horwitz RI. Problems in the conduct and analysis of randomized clinical trials. Are we getting the right answers to the wrong questions? JAMA Internal Medicine 1992, 152: 507-12. PMID: 1546913, DOI: 10.1001/archinte.152.3.507.Peer-Reviewed Original Research